Results 171 to 180 of about 63,048 (236)

Recalculation of inhibitor concentration fold-changes for CMY-219: comments on a recent article about CMY-219 conferring resistance to ceftazidime-avibactam. [PDF]

Antimicrob Agents Chemother
Feng C.
europepmc   +1 more source

Outcome of Ceftazidime/Avibactam Versus Alternative Antibiotics for Treatment of Carbapenem-Resistant <i>Enterobacterales</i> Bacteremia in Patients With Hematologic Malignancies. [PDF]

J Korean Med Sci
Jang HM, Baek S, Lim SY, Bae S, Park H, Park HS, Choi Y, Lee JH, Lee JH, Kim SH.   +9 more
europepmc   +1 more source

Newer antibiotics for drug-resistant Gram-negative infections in immunocompromised hosts: from pivotal trials to high-risk practice. [PDF]

Front Cell Infect Microbiol
Sun Y, Guo Y, Cui H, Jiang Y, Yu Q.
europepmc   +1 more source

Next-Generation Sequencing in Melioidosis: Enhancing Diagnosis, Epidemiology and Antimicrobial Resistance Surveillance. [PDF]

Diagnostics (Basel)
Wu H, Zhang P, Li S, Zhao H.
europepmc   +1 more source

Successful Rapid Desensitization to Ceftazidime/Avibactam in a Patient With Cystic Fibrosis and Multidrug-Resistant <i>Pseudomonas aeruginosa</i> Pneumonia: A Case Report. [PDF]

Clin Case Rep
Zhou Z, Zhu J, Wu G, Kang X, Wang Q, Liu J, Jiang Y.   +6 more
europepmc   +1 more source

When might we consider using the newer β-lactam agents as empirical therapy against presumed carbapenem-resistant gram-negative infections? [PDF]

JAC Antimicrob Resist
Assimakopoulos SF, Ioannou S, Rodriguez-Bano J, Marangos M, Daikos GL.   +4 more
europepmc   +1 more source

Rapid MALDI-TOF MS antimicrobial susceptibility testing with the MBT FAST assay. [PDF]

J Clin Microbiol
Idelevich EA, Alpers K, Buhl M, Drews O, Kidd SP, Kostrzewa M, Moore N, Nix ID, Oberheitmann B, Pereira F, Pranada A, Scholz I, Walter C, Sparbier K, Spüler M, Steinmann J, Weferling J, Zimmermann S, Becker K.   +18 more
europepmc   +1 more source

Trends in the Frequency and Antimicrobial Resistance of Common Gram-Negative Bacilli Isolated From Urine Cultures. [PDF]

APMIS
Castellano-Sánchez L, Rosales-Castillo A, Requena-Fernández L, Ramos-Bermúdez M, Esteban-Martín V, Gutiérrez-Fernández J.   +5 more
europepmc   +1 more source

Failure of endophthalmitis prophylaxis: laboratory model comparing antibiotics and bacterial loads. [PDF]

J Cataract Refract Surg
Moon M, Mathews S, Mahjabin F, Karaiskos K, Libre PE.   +4 more
europepmc   +1 more source

Evaluating the efficacy of ceftazidime/avibactam plus amikacin combination therapy as a carbapenem-sparing agent against ceftazidime/avibactam-resistant <i>Escherichia coli</i> using a hollow fiber infection model: a proof-of-concept study. [PDF]

Antimicrob Agents Chemother
Walker MM, Roberts JA, Li Y, Naicker S, Wallis SC, Ordonez JL, Won H, Forde BM, Sime FB.   +8 more
europepmc   +1 more source